Cancer Therapy News and Research

RSS

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT.

22 Jun 2010

Concord Medical adds two new centers by furthering partnership with Navy General Hospital

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it will add two new centers to its extensive network by furthering its partnership with the PLA Navy General Hospital, located in Beijing.

22 Jun 2010

Biodesix awarded US patent for VeriStrat serum test

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.

22 Jun 2010

Pfizer announces voluntary withdrawal of Mylotarg from U.S. market following FDA request

Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product's safety and the drug failed to demonstrate clinical benefit to patients enrolled in trials.

22 Jun 2010

Hyundai Hope on Wheels announces nationwide initiative to raise funds for childhood cancer research

Hyundai Hope on Wheels, a partnership of Hyundai dealers across the U.S. and Hyundai Motor America, today announced a new nationwide initiative to raise funds to fight childhood cancer. Hyundai dealers have pledged to donate a total of $3 million dollars to Hope on Wheels based on vehicles sold during the month of September (National Childhood Cancer Awareness Month).

19 Jun 2010

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

National Cheng Kung University Hospital's Outpatient Building inaugurated

The Outpatient Building of National Cheng Kung University Hospital was officially inaugurated on June 12th to provide excellent medical service and to further ensure the health of people in Southern Taiwan.

18 Jun 2010

Baylor University researchers awarded grant to research and test new compounds for cancer

The National Institutes of Health has awarded two Baylor University researchers a $1.46 million grant to research and test new compounds that could help fight cancerous tumors.

18 Jun 2010

Early detection helps prevent nearly thousand deaths from breast cancer each year: Research

NEARLY a thousand deaths from breast cancer could be avoided each year if short term survival rates in England were among the best comparable countries in Europe, according to research presented at the National Cancer Intelligence Network conference today.

17 Jun 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.

17 Jun 2010

“Experiment” with homeopathy killed a cancer patient: Inquest

Doctor Peter Dingle at an inquest into the events that led to the death of his wife Penelope, 45 on 25th August 2005 revealed that he had argued with her decision to go for alternative therapies as her colorectal cancer treatment.

17 Jun 2010

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.

17 Jun 2010

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Through a unanimous decision, the Florida Advisory Council on Radiation Protection has endorsed Target Safely, the American Society for Radiation Oncology's (ASTRO) patient protection plan.

16 Jun 2010

New combination appears to be effective against cancer stem cells in pancreatic cancer

The new cancer medication sorafenib looks promising. Sorafenib is used for advanced liver and kidney cancer and also appears to be effective against cancer stem cells in pancreatic cancer. The team led by Professor Dr. Ingrid Herr, Head of the Department of Molecular Oncosurgery, a group of the Department of Surgery at Heidelberg University Hospital, (Managing Director: Professor Dr. Markus W. B-chler) in cooperation with the German Cancer Research Center, tested the new substance in mice and pancreatic cancer cells.

16 Jun 2010

Galera Therapeutics completes Series 1 financing

Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc., of Columbia Missouri.

16 Jun 2010

Researchers examine rates of cancer in British white and British Indian population

British Indians have fewer cases of many different cancers including breast, prostate, colon and lung than the British white population, according to new research published in the British Journal of Cancer1 today (Wednesday).

16 Jun 2010

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

15 Jun 2010

ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variants

ExonHit Therapeutics today announced the signing of an exclusive agreement with Genmab A/S for a selection of novel splice variants, identified as part of a successful pilot study, that have the potential to be therapeutic targets for breast cancer. Genmab retains exclusive development and commercialization rights on 10 events out of a breast cancer database developed using ExonHit's genome-wide SpliceArray technology (RNA splicing analysis platform covering the entire genome).

15 Jun 2010

Cancer Therapy News and Research

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Concord Medical adds two new centers by furthering partnership with Navy General Hospital

Biodesix awarded US patent for VeriStrat serum test

Pfizer announces voluntary withdrawal of Mylotarg from U.S. market following FDA request

Hyundai Hope on Wheels announces nationwide initiative to raise funds for childhood cancer research

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

National Cheng Kung University Hospital's Outpatient Building inaugurated

Baylor University researchers awarded grant to research and test new compounds for cancer

Early detection helps prevent nearly thousand deaths from breast cancer each year: Research

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

“Experiment” with homeopathy killed a cancer patient: Inquest

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

New combination appears to be effective against cancer stem cells in pancreatic cancer

Galera Therapeutics completes Series 1 financing

Researchers examine rates of cancer in British white and British Indian population

Sulindac shuts down cancer cell growth, initiates cell death: Study

ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variants

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News